Jump to content
  • Announcements

    • Admin

      Winter vaccinations!   11/03/2016

      It is very important for people with chronic diseases, such as SLE,and for those people taking corticosteroids and immunosuppressants, including chemotherapy drugs, should go to their doctor to be immunised against flu. Flu is not a bad cold! It can be dangerous. Apart from the annual flu jab, ask your doctor about the pneumovax vaccine which will help prevent serious problems with the lungs. Those with asthma should also ask about the various kinds of vaccines available. Finally, Herpes Zoster infections can lead to the risk of strokes in certain populations which include, rheumatoid arthritis and SLE. There is a new post with information, along with a video. Be well! Ros
    • Admin

      Blogs!   03/27/2017

      All registered Members can write their own Blog here! Just click on Blog and select a title!
    • Admin

      Sign Up & Date of Birth   08/26/2017

      When you Sign Up,  Please use the following to complete the Date of Birth entry: nn-nn-nnnn where n=number. Thus, if your birthday is 5th May 1968, enter: 05-05-1968. Use the “-“ separator and not the “/“.                                                
    • Admin

      GHIC   09/08/2017

      I am excited to announce that LUpus Patients Understanding & Support (LUPUS) is linking with The Graham Hughes International Charity (GHIC). This means I will be posting articles from Professor Hughes here. About 25% of those with SLE also have Hughes Syndrome. As more research is being done, its findings are extremely important for those who have this condition. Like SLE, diagnosis can take a very long time.
Admin

Cumulative hydroxychloroquine and aspirin may prevent cardiovascular events in patients with SLE

Recommended Posts

Cumulative hydroxychloroquine and aspirin may prevent cardiovascular events in patients with SLE

In patients with lupus, ongoing use of hydroxychloroquine plus low-dose aspirin may be associated with increased effectiveness in the primary prevention of cardiovascular events, according to recently published findings.

Researchers identified 189 patients from a database of the Rheumatology Unit of the Second University of Naples. The study group included 175 women and the overall mean age at baseline was 31 years. Patients had a diagnosis of systemic lupus erythematosus (SLE) upon admission, and had never experienced a cardiovascular event (CVE). Patients were seen for follow-up every 3 months to 6 months, depending upon their clinical condition. Investigators documented any CVE that occurred during the intervening time and information about the use of aspirin (ASA) and cumulative dosages of hydroxychloroquine (c-HCQ). Researchers used Kaplan-Meier analysis to determine the cumulative dosage that yielded a lower rate of CVE. Cox regression analysis was used to determine factors linked to an initial CVE.

They found 10 patients experienced the following non-lethal thrombotic events: stroke, one patient; transient ischemic attack, five patients; and acute myocardial infarction, four patients. The mean time to the first CVE was 5 years. Four (2.1%) patients died during the course of the study; none of these deaths were related to CV complications.

Kaplan-Meier analysis demonstrated a significant disparity in CVE-free rates among the four patient subgroups. There was no difference in CVE-free rate between the 135 patients treated with ASA plus HCA and the 28 patients treated with aspirin monotherapy.

A lower rate of CVEs was reported in the c-HCQ patients. A higher CVE-free rate was documented in the 85 patients on an ASA-HCA regimen who had arrived at a cHCQ dosage greater than 600 g than in the 28 patients who were treated with ASA monotherapy or the 51 patients treated with ASA/cHCQ at a dosage less than 600g. There were no differences in traditional CV risk factors and those specific to SLE among the patient groups, nor were there differences between medications (statins, high-dose steroids).

Multivariate analysis revealed that cumulative treatment with hydroxychloroquine, when added to ASA, was thromboprotective. High blood pressure and antiphospholipid antibody positivity were identified as predictive of an initial CVE.

 

Serena Fasano
Serena Fasano

 

“Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. This study was performed to investigate the role of aspirin and distinct hydroxychloroquine cumulative dosages and treatment durations,” researcher Serena Fasano told Healio/Rheumatology. “We found that aspirin and antimalarials, when administered for more than 5 years at a cumulative dosage greater than 600 g, may reduce the CVE risk in SLE patients.” – by Jennifer Byrne

 

Disclosure: The researchers report no relevant disclosures.

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×